Yimin Huang

Yimin Huang

Auto-generated profile, based on publicly available information

Yimin Huang

Research, Biogen

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in eLife
Verified
Journal Article
Open access
RSRui P Silva
Rui P Silva
YHYimin Huang
Yimin Huang
ANAnnalee W Nguyen
Annalee W Nguyen
CHChing-Lin Hsieh
Ching-Lin Hsieh
OOOladimeji S Olaluwoye
Oladimeji S Olaluwoye
JMJennifer Maynard
Jennifer Maynard
To address the ongoing SARS-CoV-2 pandemic and prepare for future coronavirus outbreaks, understanding the protective potential of epitopes conserved across SARS-CoV-2 variants and coronavirus lineages is essential. We describe a highly conserved, conformational S2 domain epitope present only in the prefusion core of β-coronaviruses: SARS-CoV-2 S2 apex residues 980–1006 in the flexible hinge. Antibody RAY53 binds the native hinge in MERS-CoV and SARS-CoV-2 spikes on the surface of mammalian cells and mediates antibody-dependent cellular phagocytosis and cytotoxicity against SARS-CoV-2 spike in vitro. Hinge epitope mutations that ablate antibody binding compromise pseudovirus infectivity, but changes elsewhere that affect spike opening dynamics, including those found in Omicron BA.1, occlude the epitope and may evade pre-existing serum antibodies targeting the S2 core. This work defines a third class of S2 antibody while providing insights into the potency and limitations of S2 core epitope targeting.

28 August 2023 in Glia
Verified
Journal Article
Open access
XCXuezhen Chen
Xuezhen Chen
YZYue Zhao
Yue Zhao
YHYimin Huang
Yimin Huang
KZKaichuan Zhu
Kaichuan Zhu
FZFan Zeng
Fan Zeng
XXXianyuan Xiang
Xianyuan Xiang
Triggering receptor expressed on myeloid cell 2 (TREM2), a myeloid cell‐specific signaling molecule, controls essential functions of microglia and impacts on the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. TREM2 is also highly expressed in tumor‐associated macrophages in different types of cancer. Here, we studied whether TREM2 influences glioma progression. We found a gender‐dependent effect of glioma growth in wild‐type (WT) animals injected with GL261‐EGFP glioma cells. Most importantly, TREM2 promotes glioma progression in male but not female animals. The accumulation of glioma‐associated microglia/macrophages (GAMs) and CD31+ blood vessel density is reduced in male TREM2‐deficient mice. A transcriptomic analysis of glioma tissue revealed that TREM2 deficiency suppresses immune‐related genes. In an organotypic slice model devoid of functional vascularization and immune components from periphery, the tumor size was not affected by TREM2‐deficiency. In human resection samples from glioblastoma, TREM2 is upregulated in GAMs. Based on the Cancer Genome Atlas Program (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases, the TREM2 expression levels were negatively correlated with survival. Thus, the TREM2‐dependent crosstalk between GAMs and the vasculature formation promotes glioma growth.

5 March 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
JPJuyeon Park
Juyeon Park
LLLisa Lindesmith
Lisa Lindesmith
AOAdam S. Olia
Adam S. Olia
VCVeronica P. Costantini
Veronica P. Costantini
PBPaul D. Brewer-Jensen
Paul D. Brewer-Jensen
RBRalph S. Baric
Ralph S. Baric
Human norovirus causes more than 700 million illnesses annually. Extensive genetic diversity and a paucity of information on conserved neutralizing epitopes pose major obstacles to the design of broadly protective norovirus immunogens. Here, we used high-resolution liquid chromatography–tandem mass spectrometry (LC-MS/MS)–driven proteomics to quantitatively characterize the circulating serum IgG repertoire before and after immunization with an experimental monovalent norovirus GII.4 VP1 capsid–encoding adenoviral vaccine. Two participants were specifically selected on the basis of the breadth of serum neutralization responses either across GII.4 variants (participant A) or across GII genotypes (participant B). In participant A, vaccination back-boosted highly abundant serum antibody clonotypes targeting epitopes conserved among rapidly evolving GII.4 variants spanning from a strain identified in 1987 to a strain identified in 2019. In participant B, we identified a recall response consisting of broadly neutralizing monoclonal antibodies with remarkable cross-GII ligand-binding blockade (blocking ≥ seven GII genotypes) and virus neutralization breadth. The cocrystal structure of one of these antibodies, VX22, in complex with the VP1 capsid protruding (P) domain revealed a highly conserved epitope (residues 479 to 484 and 509 to 513) within two lateral loops of the P1 subdomain. Antibody evolutionary trajectory analysis further revealed that VX22 had originally evolved from an early heterologous infection, likely by a GII.12 strain. Together, our study demonstrates that norovirus human monoclonal antibodies with broad GII.4 potency and cross-GII breadth can be boosted in serum after immunization with an adenoviral vector–based vaccine, findings that may guide the design of immunogens for broadly protective norovirus vaccines.

27 August 2018 in Cellular Microbiology
Verified
Journal Article
Open access
PDF file
EAEdith Acquaye-Seedah
Edith Acquaye-Seedah
YHYimin Huang
Yimin Huang
JSJamie N. Sutherland
Jamie N. Sutherland
ADAndrea M. DiVenere
Andrea M. DiVenere
JMJennifer Maynard
Jennifer Maynard
Pertussis toxin (PTx) is a major protective antigen produced by Bordetella pertussis that is included in all current acellular vaccines. Of several well‐characterized monoclonal antibodies binding this toxin, the humanised hu1B7 and hu11E6 antibodies are highly protective in multiple in vitro and in vivo assays. In this study, we determine the molecular mechanisms of protection mediated by these antibodies. Neither antibody directly binds the B. pertussis bacterium nor supports antibody‐dependent complement cytotoxicity. Both antibodies, either individually or as a cocktail, form multivalent complexes with soluble PTx that bind the FcγRIIb receptor more tightly than antibody alone, suggesting that the antibodies may accelerate PTx clearance via immune complex formation. However, a receptor binding assay and cellular imaging indicate that the main mechanism used by hu11E6 is competitive inhibition of PTx binding to its cellular receptor. In contrast, the main hu1B7 neutralising mechanism appears to be inhibition of PTx internalisation and retrograde trafficking. We assessed the effects of hu1B7 on PTx retrograde trafficking in CHO‐K1 cells using quantitative immunofluorescence microscopy. In the absence of hu1B7 or after incubation with an isotype control antibody, PTx colocalizes to organelles in a manner consistent with retrograde transport. However, after preincubation with hu1B7, PTx appears restricted to the membrane surface with colocalization to organelles associated with retrograde transport significantly reduced. Together, these data support a model whereby hu11E6 and hu1B7 interfere with PTx receptor binding and PTx retrograde trafficking, respectively.

20 March 2026 in mAbs
Verified
Journal Article
Open access
SASamad Amini
Samad Amini
YHYimin Huang
Yimin Huang
MJMark Julian
Mark Julian
CPChristina Palmer
Christina Palmer
SSSimone Sciabola
Simone Sciabola
YWYe Wang
Ye Wang
1. Monoclonal antibodies (mAbs) have emerged as one of the most successful classes of biotherapeutics, with over 200 FDA-approved antibodies currently in clinical use.1,2 Their high specificity and...

12 May 2008 in Cybernetics and Systems
Verified
Journal Article
Open access
MVMarco Valtorta
Marco Valtorta
YHYimin Huang
Yimin Huang
In this article we describe an important structure used to model causal theories and a related problem of great interest to semi-empirical scientists. A causal Bayesian network is a pair consisting of a directed acyclic graph (called a causal graph) that represents causal relationships and a set of probability tables, that together with the graph specify the joint probability of the variables represented as nodes in the graph. We briefly describe the probabilistic semantics of causality proposed by Pearl for this graphical probabilistic model, and how unobservable variables greatly complicate models and their application. A common question about causal Bayesian networks is the problem of identifying causal effects from nonexperimental data, which is called the identifability problem. In the basic version of this problem, a semi-empirical scientist postulates a set of causal mechanisms and uses them, together with a probability distribution on the observable set of variables in a domain of interest, to predict the effect of a manipulation on some variable of interest. We explain this problem, provide several examples, and direct the readers to recent work that provides a solution to the problem and some of its extensions. We assume that the Bayesian network structure is given to us and do not address the problem of learning it from data and the related statistical inference and testing issues.